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Abstract Progress in the cell cycle is governed by the activity of
cyclin dependent kinases (Cdks). Unlike other Cdks, the Cdk5
catalytic subunit is found mostly in differentiated neurons.
Interestingly, the only known protein that activates Cdk5 (i.e.
p35) is expressed solely in the brain. It has been suggested that,
besides its requirement in neuronal differentiation, Cdk5 activity
is induced during myogenesis. However, it is not clear how this
activity is regulated in the pathway that leads proliferative cells
to differentiation. In order to find if there exists any Cdk5-
interacting protein, the yeast two-hybrid system was used to
screen a HeLa cDNA library. We have determined that a C-
terminal 172 amino acid domain of the DNA binding protein,
dbpA, binds to Cdk5. Biochemical analyses reveal that this
fragment (dbpA(Cv)) strongly inhibits p35-activated Cdk5
kinase. The protein also interacts with Cdk4 and inhibits the
Cdk4/cyclin D1 enzyme. Surprisingly, dbpA(Cv) does not bind
Cdk2 in the two-hybrid assay nor does it inhibit Cdk2 activated
by cyclin A. It could be that dbpA’s ability to inhibit Cdk5 and
Cdk4 reflects an apparent cross-talk between distinct signal
transduction pathways controlled by dbpA on the one hand and
Cdk5 or Cdk4 on the other.
z 1999 Federation of European Biochemical Societies.
Key words: Cyclin dependant kinase 5;
DNA binding protein A; Kinase inhibitor;
Yeast two-hybrid system
1. Introduction
Cyclin dependent kinases (Cdks) are a class of serine/threo-
nine protein kinases which regulate important transitions in
the cell cycle. Cdk5 was initially identi¢ed on the basis of its
sequence similarity to the family of cyclin dependent kinases
[1,2]. However, Cdk5 is thought be a cyclin dependent kinase
with neuron-speci¢c function only, since its catalytic subunit
is predominantly expressed in post-mitotic cells of the nervous
system, cells which have permanently exited the cell cycle [2,3].
Moreover, the protein p35 which activates the Cdk5 enzyme is
exclusively expressed in the central nervous system (CNS)
[3,4].
Nevertheless, the catalytic subunit of Cdk5 is widely ex-
pressed at basal levels, in both cycling and non-cycling cells,
in most human tissues [2,3]. Interestingly, cyclins D and E,
activator molecules which regulate Cdk activity in proliferat-
ing cells, bind Cdk5 ([5,6] ; our own observations). It could be
argued that Cdk5 bound to cyclin D or cyclin E phospho-
rylates substrates which are not yet known.
The 35 kDa p35 protein, the only known activator of Cdk5,
which was originally isolated as a smaller 25 kDa proteolytic
product, bears no signi¢cant homology to the family of cy-
clins [3,4]. As a Cdk activator, p35 is unique since it has no
in£uence on the activity of other Cdks [2,3].
Histone H1 and the retinoblastoma protein (pRb) are sub-
strates that are frequently used to con¢rm in vitro activity of
the Cdks. Heterodimeric Cdk5/p35 and Cdk5/p25 complexes
can phosphorylate both histone H1 and pRb [3,7]. Activated
Cdk5 also phosphorylates its activating partner p35 [8]. Be-
sides, Cdk5 is known to phosphorylate in vitro a number of
neuron-speci¢c cytoskeletal proteins that includes the neuro-
¢lament proteins NF-M, NF-H, the microtubule associated
protein tau and the actin binding protein caldesmon [2,3].
Phosphorylation of cytoskeletal proteins is thought to play
an important role in the polymerization and assembly of cy-
toskeletal elements which, in turn, may a¡ect growth of neu-
rites. Indeed, Cdk5 activity has been demonstrated to play a
key role in neurite outgrowth [9] and neuronal migration dur-
ing di¡erentiation of neurons [10]. Recently, Cdk5 has been
shown to participate in the regulation of myogenesis in the
early embryo [11,12]. These observations may provide new
insight into the possible function of Cdk5 during di¡erentia-
tion.
Cdk5 is known to phosphorylate neuro¢lament proteins
exclusively at sites phosphorylated in Lewy body pathologies,
i.e. di¡use Lewy body disease (dementia), Parkinson’s disease
[13,14] and amyotrophic lateral sclerosis [2,15], and tau pro-
tein at sites phosphorylated in Alzheimer’s disease [2,3,16,17].
Moreover, it has been reported that the kinase activity of
Cdk5 correlates with the extent of di¡erentiation of neuronal
cells [2,3,18] and colocalizes with neuro¢lament tracts in the
axons of neuronal cells in culture.
It is therefore possible that Cdk5 activity is tightly regulated
in pathways that lead from cell proliferation towards di¡er-
entiation. Hence, we have inquired whether if there are any
proteins that could be involved in the regulation of Cdk5 (i.e.
may activate or inhibit the kinase) in cycling cells. With this in
mind, a cDNA library, constructed from total RNA obtained
from HeLa cells, was screened using the yeast two-hybrid
system. Amongst other proteins (unpublished observations),
we ¢nd that a C-terminal fragment of the DNA binding pro-
tein dbpA (in this communication referred to as dbpA(Cv))
interacts with the bait protein Cdk5, in the two-hybrid assay.
Conversely, when dbpA(Cv) was used as bait, the interaction
between dbpA(Cv) and Cdk5 was equally e⁄cient. The val-
idity of these interactions was corroborated using the Esche-
richia coli expressed GST-dbpA(Cv) fusion protein. The pu-
ri¢ed protein precipitates not only in vitro transcribed/
translated Cdk5 but also the protein which is expressed in
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COS-1 cells. Similar experiments reveal that dbpA(Cv) can
bind Cdk4 as well, but not Cdk2 or Cdk1. Surprisingly,
dbpA(Cv) appears to be an e⁄cient inhibitor of Cdk5/p35
and Cdk4/cyclin D1 kinase activities but fails to inhibit
Cdk2/cyclin A.
2. Materials and methods
2.1. Plasmid constructs for yeast expression
EcoRI-BglII PCR fragments of human Cdk1, Cdk2 and Cdk4 and
EcoRI-SalI PCR fragments of bovine Cdk5 and human p35 were
cloned in the pLEX-a vector [19] downstream of the LEX-a DNA
binding domain (DBD). Expression in yeast from pLEX-a plasmids
is controlled by the constitutive alcohol dehydrogenase promoter
(ADH1), and the plasmid encodes the TRP1 and ADE2 genes for
stable propagation in yeast. Furthermore, the EcoRI-SalI fragments
of Cdk5 and p35 were also cloned in the vector pGAD424 (Clontech)
in such a way that they lie directly downstream of the GAL4 tran-
scriptional activation domain (TAD). Expression from the pGAD424
plasmid, which encodes LEU2 as a marker gene, is also driven by the
ADH1 promoter.
A BamHI-SalI PCR fragment of dbpA(Cv) (the isolated HeLa
cDNA) was cloned in pLEX-a for expression in yeast. Furthermore,
a BamHI-XhoI fragment of the dbpA(Cv) was cloned in pACT2
(Clontech) whereas a BamHI-NotI fragment was cloned in pVP16
[19]. The pACT2 plasmid encodes GAL4TAD whereas the pVP16 plas-
mid encodes VP16TAD. The TADs in both plasmids are under the
control of the constitutive ADH1 promoter. The plasmids encode
LEU2 for selection in yeast. The dbpA(Cv) fragment has been cloned
directly downstream of GAL4TAD and VP16TAD .
Plasmids pLEX-a/lamin and pLEX-a/MyoD were gifts from S.M.
Hollenberg [19].
2.2. Plasmid constructs for E. coli expression
A BamHI-SalI fragment of the dbpA(Cv) cDNA was cloned in (a)
pGEX4T-1 (Amersham-Pharmacia Biotech) for expression of a GST-
dbpA(Cv) fusion protein and (b) pQE32 (Qiagen) for expression of a
His-tagged dbpA(Cv) protein.
2.3. Plasmid constructs for COS-1 cell expression and in vitro
transcription/translation
A BamHI-SalI fragment of Cdk5 was cloned in pcDNA3.13 (In-
vitrogen). The EcoRI-XhoI fragments of Cdk1, Cdk2 and Cdk4 were
cloned into pcDNA3.1+ (Invitrogen). The plasmid pcMV-L-gal was
obtained from H.-J. Keller (Novartis).
2.4. Plasmid constructs for insect cell expression
A BamHI-SalI fragment of Cdk5 was cloned in pFastBac1 (Gibco
BRL) for construction of a recombinant baculovirus. The pFastBac1
vector has a baculovirus-speci¢c promoter from Autographa califor-
nica nuclear polyhedrosis virus (AcNPV) for heterologous expression
of proteins in insect cells. Similarly, BamHI-EcoRI fragments of hu-
man Cdk2 and Cdk4 were cloned in pFastBac1 for construction of
recombinant baculoviruses.
EcoRI-SalI fragments of human p35, human cyclin A, murine cyclin
D2 and murine cyclin D3 were cloned in pFastBac1 downstream of a
BglII-EcoRI fragment of GST (PCR fragment from pGEX4T-1;
Amersham-Pharmacia Biotech) for construction of recombinant ba-
culoviruses. Similarly, an EcoRI-XhoI fragment of human cyclin D1
and a BamHI-SalI fragment of dbpA(Cv) were cloned as GST fusions
in pFastBac1.
2.5. Yeast strains and media
The Saccharomyces cerevisiae strains L40 (Mata, his3v200, trp1-
901, leu2-3,112, ade2, lys2-801am, URA3 : :(lexAop)8-lacZ,
LYS : :(lexAop)4-his3) and AMR70 (MatK, his3v200, trp1-901, leu2-
3,112, ade2, lys2-801am, URA3 : :(lexAop)8-lacZ) [19] were used for
yeast transformation and for mating assays. In order to perform the
yeast two-hybrid screen, L40 was transformed sequentially with (a)
pLEX-a/cdk5 and (b) a human HeLa S3 Matchmaker cDNA library
cloned unidirectionally into the EcoRI and XhoI sites of pGADGH
(Clontech, HL4000AA). The pGADGH vector contains the GAL4TAD
under the control of the ADH1 promoter and also encodes LEU2 as a
marker gene. In order to mate a L40 strain that was cured of bait
plasmid but still contains the prey plasmid (from the cDNA library),
transformants of AMR70 (bearing plasmids pLEX-a/cdk5 or pLEX-a/
lamin) were used. Both L40 and AMR70 contain the lacZ reporter
gene linked to the lexA operon. Besides, L40 also contains the HIS3
reporter gene downstream of the lexA operon. Untransformed yeast
strains were grown in YPAD whereas transformed yeast strains were
grown in minimal medium that allow maintenance of plasmids in a
particular strain.
The S. cerevisiae strain L40 was also used for transformation of
pLEX-a plasmids that encode Cdk1, Cdk2, Cdk4, Cdk5, p35,
dbpA(Cv), lamin or MyoD. A pACT2 or pVP16 plasmid that encodes
dbpA(Cv) or pGAD424 plasmids that encode Cdk5 and p35 were used
to perform yeast two-hybrid assays on selected transformants.
2.6. Yeast two-hybrid screen
A pLEX-a/cdk5 plasmid-bearing strain of L40 was transformed
with the HeLa cDNA library (Clontech) and transformants were se-
lected exactly as described earlier [19]. His colonies were lysed in
liquid nitrogen and assayed for L-galactosidase activity on ¢lters.
Only those colonies, which do not express L-galactosidase after loss
of the pLEX-a/cdk5 bait plasmid, were selected for further analysis.
The plasmids pLEX-a/cdk5 or pLEX-a/lamin were reintroduced into
L40 (a) by direct transformation of L40 strains that already contain
the prey plasmid or (b) by mating prey plasmid-containing L40 strains
with AMR70 transformants of pLEX-a/cdk5 or pLEX-a/lamin. Later,
the prey plasmids were isolated by transforming total yeast DNA into
HB101 and by selecting for leucine prototrophy on minimal medium
plates (manufacturer’s protocol; Clontech). Plasmids, that contain
de¢ned inserts, were then retransformed into L40 strains that already
harbor pLEX-a/cdk5 or pLex-a/lamin. Plasmids, which express pro-
teins that do not bind lamin but reproducibly interact with Cdk5,
were sequenced using an automated DNA sequencer (LiCor). Inserts
were identi¢ed by comparing translated DNA sequences with the
SWISS PROT database.
2.7. Pull-down assay with [35S]methionine-labeled Cdk1, Cdk2, Cdk4
and Cdk5
The pcDNA3.1 plasmids (1 Wg) carrying the genes Cdk1, Cdk2,
Cdk4 or Cdk5 were linearized uniquely at the 3P-end of the gene
inserts. The linearized plasmids were used as templates for in vitro
transcription/translation. The Cdk proteins were radioactively labeled
with [35S]methionine (20 WCi of an in vivo cell labeling grade; Amer-
sham-Pharmacia Biotech). The transcription and translation was per-
formed using the TNT-T7 in vitro transcription/translation kit (Prom-
ega).
Bacterially expressed glutathione S-transferase (GST) and GST-
dbpA(Cv) fusion protein were bound to glutathione Sepharose 4B
(Amersham-Pharmacia Biotech) by incubating protein and beads at
RT for 1 h. After four washing steps with 10 volumes of ice-cold PBS,
the beads were resuspended in 200 Wl 1% w/v BSA-PBS solution and
kept on ice. 5 Wl of the [35S]methionine-labeled Cdk proteins (from
100 Wl of an in vitro transcribed/translated product) diluted in 200 Wl
1% w/v BSA-PBS solution, which contained 4 Wl of a 100U solution
of universal protease inhibitors (tablet dissolved in redistilled H2O;
Boehringer Mannheim), was kept on ice for 15 min. GSH-Sepharose
4B beads, bound to GST or GST-dbpA(Cv), were incubated with
labeled Cdks at 4‡C for 2 h with gentle mixing. The beads were
washed three times with 1 ml of bead-binding bu¡er (50 mM potas-
sium phosphate pH 7.5, 150 mM KCl, 1 mM MgCl2, 10% v/v glyc-
erol, 1% v/v Triton X-100) containing universal protease inhibitors
(Boehringer Mannheim). The pelleted bead-bound protein complexes
were denatured by boiling in Laemmli sample bu¡er (4% w/v SDS, 0.1
M Tris, 4 mM EDTA, 20% v/v glycerol, 33% w/v bromophenol blue)
containing 50 mM DTT, and were analyzed by 12.5% SDS-PAGE.
The gels were ¢xed (10% v/v glacial acetic acid, 30% v/v methanol
solution) for 10 min, and the signal was enhanced by soaking the gel
in EN3HANCE (NEN) for 1 h at RT. The dried gel was exposed to
Kodak X-OMAT AR ¢lm.
2.8. Transfection of pcDNA 3.1+/cdk2, pcDNA 3.1+/cdk4 and pcDNA
3.1-/cdk5 in COS-1 cells and precipitation of COS-1 expressed
Cdks by GST-dbpA(Cv)
COS-1 cells in six-well plates, grown in Dulbecco’s modi¢ed Eagle’s
medium (DMEM, Gibco BRL) that contained 10% v/v fetal bovine
serum (FBS, Gibco BRL), were transfected with 2 Wg of pcDNA 3.1
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plasmids that carry Cdk2, Cdk4 or Cdk5, using calcium phosphate. In
order to control transformation e⁄ciency, pcMV-L-gal was used.
Harvested cells (V5U105) were washed once with PBS and then
lysed in 1 ml of hypotonic lysis bu¡er (10 mM Tris-HCl pH 7.4, 10
mM NaCl, 3 mM MgCl2, 0.5% v/v Nonidet P-40) that contained
1 mM DTT and universal protease inhibitors (Boehringer Mann-
heim). Total protein in cell lysates was measured by the Bradford
assay (Bio-Rad) and was stored at 370‡C before use.
400 Wl of a COS-1 cell lysate was ¢rst preincubated for 2 h at 4‡C
with 30 Wl of Sepharose 4B (to remove unspeci¢c binding of proteins
to beads). This was followed by incubation with 30 Wl of GSH-
Sepharose 4B that was already bound to bacterially expressed GST-
dbpA(Cv). Pull-down of the Cdks in COS-1 cell lysates was per-
formed as described above for the [35S]methionine-labeled Cdks.
The pelleted bead-bound protein complexes were denatured by boiling
in Laemmli sample bu¡er and were analyzed by Western blotting. The
blots were probed with polyclonal antibodies raised against Cdk2 and
N-terminal fragments of Cdk4 and Cdk5 and were detected by ECL
(Amersham-Pharmacia Biotech).
2.9. Northern blotting
25 ng of pcDNA3.1+ encoding the dbpA(Cv) gene was used to
make a labeled probe for Northern blotting (1.9U109 dpm/Wg) using
the rediprime DNA labeling system (Amersham-Pharmacia Biotech,
RPN1633) with Redivue [32P]dCTP (speci¢c activity = 3000 Ci/mmol;
Amersham-Pharmacia Biotech). The probe was used to hybridize a
human multiple tissue Northern blot according to the manufacturer’s
protocol (Clontech). The blot was quanti¢ed using a phosphorimager
(Molecular Devices).
2.10. Expression of baculoviruses
Recombinant baculoviruses encoding di¡erent genes were con-
structed using protocols provided by the manufacturer (Gibco
BRL). The viruses were harvested and ampli¢ed until a desired titer
was reached (viz. 1U108 pfu/ml).
2U107 Sf9 cells were used to co-infect baculoviruses carrying Cdk5,
Cdk4 or Cdk2 with GST-p35, GST-cyclin A, GST-cyclin D1, GST-
cyclin D2 or GST-cyclin D3 in 25 ml of SF900 II SFM medium
(Gibco BRL). Triple infections were performed with the above men-
tioned viral combinations and baculoviruses carrying GST-dbpA(Cv).
After 72 h, cells were harvested and lysed by sonication in NETN
bu¡er (20 mM Tris-HCl pH 8.0, 100 mM NaCl, 1 mM EDTA, 05%
v/v NP-40, 5 mM NaF, 30 mM p-NPP, 1 mM PMSF, 1 Wg/ml anti-
pain) that contained universal protease inhibitors (Boehringer Mann-
heim). HBT bu¡er (50 mM HEPES pH 7.6, 150 mM NaCl, 1 mM
EDTA, 2.5 mM EGTA, 0.1% v/v Tween 20, 1 mM DTT, 5 mM NaF,
30 mM p-NPP, 25 mM L-glycerolphosphate, 1 mM PMSF, 1 Wg/ml
antipain) was used to lyse cells that were co-infected with GST-cyclin
D1, D2 or D3 viruses. Heterodimeric enzyme complexes were isolated
by binding to 100 Wl of GSH-Sepharose 4B, overnight at 4‡C. The
beads were washed seven times with ice-cold NETN bu¡er (or HBT
bu¡er) and three times with ice-cold kinase bu¡er (20 mM Tris-HCl
pH 7.5, 10 mM MgCl2). The beads were resuspended in 100 Wl kinase
bu¡er and kept on ice before a kinase assay was performed.
2.11. Kinase assays
Phosphorylation of 0.1 Wg histone H1 (type III-S: from calf thy-
mus, Sigma H-5505) or 0.25 Wg GST-Rb152 (i.e. C-terminal 152 ami-
no acid residues of pRb covalently linked to GST; Santa Cruz Bio-
technology) was performed in kinase bu¡er for 40 min at 30‡C using
2 Wl of beads, 10 WM ATP and 3 WCi [Q-33P]ATP (speci¢c activ-
ity = 3000 Ci/mmol; Amersham-Pharmacia Biotech) in a total volume
of 10 Wl. The reactions were boiled in Laemmli sample bu¡er and were
analyzed by 12.5% SDS-PAGE. The gel was ¢xed and the phospho-
rylation was quanti¢ed using a phosphorimager (Molecular Devices).
3. Results
3.1. A C-terminal fragment of dbpA binds to Cdk5 in a yeast
two-hybrid screen
Cdk5 has been used as a bait in the yeast two-hybrid system
to screen for proteins that may interact with Cdk5. Since
Cdk5 is expressed in both cycling and non-cycling cells, we
thought it would be interesting to know if there are any Cdk5
binding proteins in cycling cells. Hence, a HeLa cDNA library
in the yeast vector pGADGH was transformed into the yeast
strain L40 [19] that already contained the bait plasmid pLEX-
a/cdk5 (which encodes LexaDBD-Cdk5). Genes encoding inter-
acting proteins were identi¢ed by selecting for His proto-
trophs and subsequently through induction of L-galactosidase
(L-gal) activity. Colonies that were His and blue were con-
sidered positive and were used for further analysis (results not
shown). It was later found that one such positive yeast colony
harbored a cDNA library plasmid (i.e. the prey plasmid) en-
coding GAL4TAD fused to a C-terminal fragment of the hu-
man gene for the DNA binding protein, dbpA (in this com-
munication referred to as dbpA(Cv) ; Fig. 2A).
In order to eliminate the possibility that an identi¢ed pos-
itive colony was an artifact of the two-hybrid system (fre-
quently referred to as ‘false positives’) [20], the yeast strain
was cured of the bait plasmid pLEX-a/cdk5 by growing the
strain in a non-selective medium (50 generations of growth in
minimal medium that contained tryptophan and adenine but
lacked leucine; the prey plasmid contains LEU2). The result-
ing L40 strain (MATa) that contains the prey plasmid,
pGADGH/dbpA(Cv), was mated with strains of AMR70
(MATK) that had been transformed either with pLEX-a/
cdk5 or with pLEX-a/lamin. L-Gal assays performed on
mated diploid strains showed that dbpA(Cv) speci¢cally in-
teracts with Cdk5 but not with lamin (Fig. 1A).
At this stage, the pGADGH/dbpA(Cv) plasmid was iso-
lated from yeast (via transformation of total yeast DNA in
E. coli ; see Section 2). The insert was sequenced and it re-
vealed that the cloned gene encoded 172 amino acids of the C-
terminal fragment of human dbpA (Fig. 2A). The dbpA(Cv)
cDNA was ampli¢ed by PCR from the pGADGH plasmid
and was subcloned into pACT2, another yeast vector often
used for two-hybrid assays. The plasmid pACT2/dbpA(Cv)
(which encodes GAL4TAD-dbpA(Cv) fusion protein) was
transformed into the strain L40 that already contained
pLEX-a/cdk5, pLEX-a/lamin, pLEX-a/MyoD or pLEX-a/
p35 (all plasmids code for LexaDBD fusion proteins). The re-
sults reiterate that, at least in the two-hybrid system, Cdk5
not only binds p35 (Cdk5’s known activator) but also inter-
acts with dbpA(Cv) (Fig. 1B, left and right panels). It was
also found that interaction of dbpA(Cv) with Cdk5 does not
depend on the speci¢c TAD to which dbpA(Cv) is linked.
This was supported by the observation that a VP16TAD-
dbpA(Cv) fusion protein binds as well as GAL4TAD-dbpA(Cv)
to LexaDBD-Cdk5, in the two-hybrid assay (data not shown).
Furthermore, the dbpA(Cv) was cloned in pLEX-a and cdk5
in pGAD424. It was seen that interchanging the two domains,
TAD and DBD, did not a¡ect the interaction between
dbpA(Cv) and Cdk5 (i.e. LexaDBD-dbpA(Cv) fusion protein
bound strongly to GAL4TAD-Cdk5; Fig. 1C). All these obser-
vations prove beyond doubt that neither a TAD nor a DBD
has any in£uence on the Cdk5-dbpA(Cv) interaction.
We also wanted to ¢nd out if Cdk5 was the only Cdk to
which dbpA(Cv) has a⁄nity. In order to test this, yeast strain
L40 was ¢rst transformed with pLEX-a/cdk5, pLEX-a/cdk4,
pLEX-a/cdk2 or pLEX-a/cdk1. The plasmid pACT2/dbpA(Cv)
(which encodes GAL4TAD-dbpA(Cv)) was then transformed
into L40 strains that already had the ability to express Lexa-
Cdk5, Lexa-Cdk4, Lexa-Cdk2 or Lexa-Cdk1 fusion proteins.
A L-gal assay (Fig. 1D) depicts that, in the yeast-two-hybrid
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system, dbpA(Cv) can interact with Cdk5 and Cdk4 but not
with Cdk2 and Cdk1.
3.2. The dbpA(Cv) protein precipitates 35S-labeled Cdk5 and
Cdk4
In order to con¢rm some of the yeast two-hybrid data, a set
of in vitro pull-down experiments were employed. We found
that bacterially expressed GST-dbpA(Cv) fusion protein (Fig.
2B) was able to pull down [35S]methionine-labeled Cdk5 and
Cdk4 but not Cdk2 and Cdk1 (all proteins were transcribed/
translated in vitro). We were sure that the GST moiety in
GST-dbpA(Cv) did not play a role in the precipitation of
Cdk5 or Cdk4 since the GST protein alone is not able to
pull down Cdk5 (Fig. 2C).
3.3. The dbpA(Cv) protein precipitates Cdk5 and Cdk4
expressed in COS-1 cells
As an alternative to the in vitro transcription/translation
procedure to obtain desired proteins, Cdk5, Cdk4 and Cdk2
were expressed in COS-1 cells. Lysates from transfectants
were incubated with the E. coli expressed GST-dbpA(Cv) fu-
sion protein. The bound proteins were detected by Western
blotting, using antibodies speci¢c to Cdk5, Cdk4 or Cdk2.
Similar to our earlier observations with labeled proteins, we
observed that GST-dbpA(Cv) was able to bind COS-1-ex-
pressed Cdk5 and Cdk4 whereas it was unable to pull-down
Cdk2 (Fig. 2D).
3.4. Tissue speci¢c expression of dbpA
The dbpA(Cv) cDNA was labeled with 32P and a human
multiple tissue Northern blot was probed. The dbpA mRNA
was relatively abundant in skeletal muscle tissue and the heart
(Fig. 3), corroborating earlier ¢ndings of Kudo et al. [21].
Since Cdk5 has been demonstrated to play a role in muscle
di¡erentiation [11,12] we were interested to ¢nd out what
e¡ect dbpA(Cv) would have on the Cdk5 kinase.
3.5. Inhibition of the Cdk5 kinase by bacterially expressed
GST-dbpA(Cv) and His-dbpA(Cv)
The Cdk5/GST-p35 heterodimeric complex was expressed
in insect cells using the baculovirus expression system. The
enzyme was puri¢ed by binding to GSH-Sepharose 4B. The
bead-bound enzyme was tested for activity (see Section 2)
using histone H1 as a substrate. Fig. 4A (lane 1) portrays
the phosphorylation of histone H1 by GST-p35 activated
Cdk5 kinase. Kinase assays performed on GST-dbpA(Cv)
demonstrate that dbpA(Cv) is not phosphorylated by Cdk5
and therefore cannot be a Cdk5 substrate (Fig. 4A, lane 3).
We then asked if dbpA(Cv) could be an inhibitor of Cdk5.
Fig. 4B shows a dose-dependent inhibition of Cdk5 by GST-
dbpA(Cv). It should be noted that, whereas 10 Wg of GST did
not have any e¡ect on the kinase (Fig. 4B, lane 8), 0.4 Wg of
GST-dbpA(Cv) distinctly inhibited the complex (s 50%; Fig.
4B, lane 5). Staurosporine (CGP39360, Novartis), which
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Fig. 1. In a yeast two-hybrid assay the C-terminal fragment of DNA binding protein dbpA binds to Cdk5 and Cdk4. Interactions were moni-
tored by analyzing six individual colonies by colorimetric L-galactosidase assays. A: After curing the bait plasmid, a L40 strain that retains the
prey plasmid (which encodes GAL4TAD-dbpA(Cv) fusion protein) was mated with strain AMR70 that had already been transformed with
pLEX-a/lamin or pLEX-a/Cdk5 (these plasmids express Lex-a-lamin and Lex-a-Cdk5 fusion proteins, respectively). The results show that
dbpA(Cv) interacts with Cdk5 but not with the unspeci¢c protein, lamin. B: Left panel, plasmid pACT2/dbpA(Cv) (which expresses
GAL4TAD-dbpA(Cv)) was transformed in strain L40 that already contains pLEX-a/lamin, pLEX-a/MyoD, pLEX-a/Cdk5 or pLEX-a/p35. The
results show that dbpA(Cv) interacts speci¢cally with Cdk5. Right panel, plasmid pGAD424/p35 (expressing GAL4TAD-p35) was transformed
in the same L40 yeast strains (see left panel), as a control. C: Plasmids pGAD424/Cdk5 (left panel) and pGAD424/p35 (right panel, as negative
control) were transformed into L40 strains that already harbor pLEX-a/dbpA(Cv) or pLEX-a/p35. Results show that Cdk5 and dbpA(Cv) can
still interact with each other even after interchanging the two domains (GAL4TAD and Lex-aDBD) which has to be linked to two putative inter-
acting proteins, in the two-hybrid assay. D: Plasmids pACT2/dbpA(Cv) (left panel) and pACT2/p35 (right panel, as control), which express
GAL4TAD-dbpA(Cv) and GAL4TAD-p35 respectively, were transformed in L40 strains that already harbor pLEX-a/Cdk5, pLEX-a/Cdk4,
pLEX-a/Cdk2 or pLEX-a/Cdk1. Results show that dbpA(Cv) interacts speci¢cally with Cdk5 and Cdk4.
M. Moorthamer et al./FEBS Letters 446 (1999) 343^350346
strongly inhibits most Cdks including Cdk5, was used as a
control inhibitor [22].
It can be argued that the relatively large GST moiety causes
a steric hindrance in the fusion protein so that it interferes
with dbpA(Cv)’s ability to act as a substrate for Cdk5 or that
the presence of GST causes an artifactual inhibition of Cdk5.
Therefore, dbpA(Cv) was expressed in E. coli as a His-tagged
protein (six consecutive histidines attached to the protein at its
N-terminus, as in pQE32; see Section 2). His-dbpA(Cv) was
used to probe if it is a substrate or an inhibitor of the Cdk5/
p35 kinase. Like GST-dbpA(Cv), His-dbpA(Cv) is not phos-
phorylated by Cdk5/GST-p35 (Fig. 4D, right panel, lane 4).
Again similar to GST-dbpA(Cv), His-dbpA(Cv) inhibits the
Cdk5/GST-p35 complex in a dose-dependent manner. His-
dbpA(Cv) completely abolishes the Cdk5-mediated phospho-
rylation of histone H1 (Fig. 4C, left panel). The His-tagged
protein can also completely inhibit the phosphorylation of
GST-Rb152 by the Cdk5/GST-p35 complex (Fig. 4C, right
panel, lane 4 and 5). Kinase assays performed with Cdk5/
GST-p35 enzyme eluted from the GSH-Sepharose 4B beads
gave identical results (results not shown).
3.6. Activation of Cdk5 with D-type cyclins
Since D-type cyclins are reported to bind Cdk5 [5], we
wanted to ¢nd out if cyclin D formed a complex with Cdk5
when both proteins are expressed in insect cells, and if it did,
whether the complex formed an active kinase by phosphoryl-
ating either histone H1 or GST-Rb152. One could speculate
that an active cyclin D/Cdk5 enzyme, with no known cellular
substrate, may phosphorylate the Cdk5 binding protein,
dbpA(Cv). Hence, Sf9 insect cells were co-infected with bacu-
loviruses encoding Cdk5 and GST-cyclin D1, GST-cyclin D2
or GST-cyclin D3. The cyclin D-bound Cdk5 proteins ob-
tained from insect cells were precipitated with GSH-Sepharose
4B and the bead-bound complexes (as con¢rmed by Western
blotting using antibodies speci¢c for Cdk5 and D-type cy-
clins; results not shown) were used directly for kinase assays.
We observed that neither GST-cyclin D1 nor GST-cyclin D3
can activate Cdk5 (results not shown). Surprisingly, like cyclin
D2-activated Cdk2 (Fig. 4D, left panel, lane 2) and Cdk4
(Fig. 4D, left panel, lane 4), kinases that are known to phos-
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Fig. 3. Tissue-speci¢c expression of dbpA. Human multiple tissue
Northern blot (Clontech) hybridized with dbpA(Cv).
Fig. 2. A: Model of DNA binding protein dbpA. The gray area is the C-terminal fragment of dbpA (172 aa) which we have found to interact
with Cdk5 and Cdk4. This area contains K-helices, basic and acidic stretches which are important in protein-protein interactions. The black
area is the cold shock domain, this region is homologous in all Y-box binding proteins and is presumed to be the DNA binding domain [24].
B: Coomassie stain of 0.1 Wg E. coli and 1 Wg insect cell (Sf9) expressed GST-dbpA(Cv) and Western blot of 0.1 Wg E. coli and 0.1 Wg insect
cell (Sf9) expressed GST-dbpA(Cv) using a monoclonal antibody against GST (Clontech). C: GST-dbpA(Cv) (referred to as (Cv)) binds to
35S-labeled Cdk4 and Cdk5 and not to 35S-labeled Cdk1 and Cdk2. Lane 1, 10% of the 35S-labeled Cdk1 input used for the pull-down assay
with (Cv) (as in lane 2); lane 3, 10% of the 35S-labeled Cdk2 input used for the pull-down assay with (Cv) (as in lane 4); lane 5, 10% of the
35S-labeled Cdk4 input used for the pull-down assay with (Cv) (as in lane 6); lane 7, 10% of the 35S-labeled Cdk5 input used for the pull-
down assay with (Cv) (as in lane 8) and the pull-down assay with GST alone (as in lane 9). D: GST-dbpA (Cv) binds to Cdk4 and Cdk5 and
not to Cdk2 overexpressed in COS-1 cells. Each lane shows a Western blot of proteins fractionated on a 10% SDS-polyacrylamide gel. Polyclo-
nal antibodies raised against Cdk2 and the N-termini of Cdk4 and Cdk5 were used to detect the respective proteins. Lanes 1, 3 and 5, 15 Wl of
lysates from COS-1 cells expressing Cdk2, Cdk4 or Cdk5. Lanes 2, 4 and 6, 400 Wl of same cell lysates, used in pull-down assays with GST-
dbpA(Cv) (referred to as (Cv)).
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phorylate pRb, cyclin D2-activated Cdk5 also has the ability
to phosphorylate GST-Rb152 (Fig. 4D, left panel, lane 6).
However, His-dbpA(Cv) is not phosphorylated by cyclin D2
and p35 activated Cdk5 (Fig. 4D, right panel, lanes 4 and 8).
3.7. Inhibition of the Cdk4 kinase by bacterially expressed
His-dbpA(Cv)
Since dbpA(Cv) interacts not only with Cdk5 but also with
Cdk4 in both two-hybrid and in vitro binding assays, the
e¡ect of His-dbpA(Cv) on active Cdk4/cyclin D1 complex
was investigated. We see that the His-tagged protein com-
pletely inhibits Cdk4/GST-cyclin D1 mediated phosphoryla-
tion of GST-Rb152 (Fig. 5A, lane 4). Furthermore, dbpA(Cv)
is de¢nitely not a substrate for the Cdk4/GST-cyclin D1 en-
zyme (Fig. 5A, lane 5).
3.8. Speci¢city of inhibition of the Cdk5 kinase compared to the
Cdk2 kinase
Although His-dbpA(Cv) inhibits the Cdk5/GST-p35 medi-
ated phosphorylation of histone H1 (there is at least a 20-fold
decrease in activity; compare lanes 3 and 4 in Fig. 5B), it
seems that phosphorylation of the same substrate by Cdk2/
GST-cyclin A is not a¡ected at all (Fig. 5B, compare lanes 1
and 2). This seems to corroborate our earlier two-hybrid data
which indicated that dbpA(Cv) does not interact with Cdk2
but binds Cdk4 and Cdk5.
3.9. Triple infections with GST-DbpA(Cv) baculoviruses
do not yield active Cdk5 or Cdk4 kinases
Sf9 insect cells were infected with three baculoviruses en-
coding (a) Cdk5, GST-p35 and GST-dbpA(Cv), (b) Cdk4,
GST-cyclin D1 and GST-dbpA(Cv), or (c) Cdk2, GST-cyclin
A and GST-dbpA(Cv). Proteins were precipitated using GSH-
Sepharose. Western blot analysis showed that all three pro-
teins were expressed in each precipitate. Kinase assays per-
formed on the GSH-Sepharose puri¢ed enzymes (according
to Section 2) yielded inactive kinases for Cdk5 and Cdk4
whereas the Cdk2 kinase was still active (results not shown).
3.10. Inhibition of the Cdk5 and Cdk4 kinase by insect cell
expressed GST-DbpA(Cv)
GST-dbpA(Cv) was puri¢ed from Sf9 insect cells using the
baculovirus expression system (Fig. 2B) and used in Cdk5/
GST-p35, Cdk4/GST-cyclin D1 and Cdk2/GST-cyclin A kin-
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Fig. 4. Kinase assays with histone H1 and GST-Rb152, as substrates, show that both GST-dbpA(Cv) and His-dbpA(Cv) proteins are not sub-
strates for Cdk5 that is activated by p35 or cyclin D2. However, GST-dbpA(Cv) and His-dbpA(Cv) inhibit Cdk5-mediated phosphorylation of
histone H1 and GST-Rb152 in a dose-responsive manner. A: GST-dbpA(Cv) is not phosphorylated by p35 activated Cdk5 kinase. Lane 1,
Cdk5/GST-p35+10 Wg histone H1 as substrate; lane 2, Cdk5/GST-p35+10 Wg GST as substrate; lane 3, Cdk5/GST-p35+0.4 Wg GST-dbpA(Cv)
as substrate. B: Dose response to GST-dbpA(Cv) in the inhibition of Cdk5-mediated phosphorylation of histone H1 (1 Wg). Lane 1, Cdk5/
GST-p35+no substrate; lane 2, Cdk5/GST-p35+substrate; lane 3, Cdk5/GST-p35+substrate+0.4 Wg GST-dbpA(Cv) ; lane 4, Cdk5/GST-
p35+substrate+0.8 Wg GST-dbpA(Cv) ; lane 5, Cdk5/GST-p35+substrate+1.6 Wg GST-dbpA(Cv); lane 6, Cdk5/GST-p35+substrate+300 nM
staurosporine; lane 7, Cdk5/GST-p35+substrate+40 nM staurosporine; lane 8, Cdk5/GST-p35+substrate+10 Wg GST. C: Left panel, dose re-
sponse to His-dbpA(Cv) in the inhibition of Cdk5-mediated phosphorylation of histone H1 (0.1 Wg). Lane 1, Cdk5/GST-p35+no substrate;
lane 2, Cdk5/GST-p35+substrate; lane 3, Cdk5/GST-p35+substrate+0.5 Wg His-dbpA(Cv) ; lane 4, Cdk5/GST-p35+substrate+1 Wg His-
dbpA(Cv) ; lane 5, Cdk5/GST-p35+substrate+3 Wg His-dbpA(Cv) ; lane 6, Cdk5/GST-p35+substrate+6 Wg His-dbpA(Cv). Right panel, dose re-
sponse to His-dbpA(Cv) in the inhibition of Cdk5-mediated phosphorylation of GST-Rb152 (0.25 Wg). Lane 1, Cdk5/GST-p35+no substrate;
lane 2, Cdk5/GST-p35+substrate; lane 3, Cdk5/GST-p35+substrate+0.5 Wg His-dbpA(Cv) ; lane 4, Cdk5/GST-p35+substrate+1 Wg His-
dbpA(Cv) ; lane 5, Cdk5/GST-p35+substrate+6 Wg His-dbpA(Cv). D: His-dbpA(Cv) is not a substrate for Cdk5/GST-p35 and Cdk5/GST-cy-
clin D2 kinases. Left panel, GST-cyclin D2-activated kinases were prepared and were tested for their ability to phosphorylate 0.25 Wg GST-
Rb152. Lane 1, Cdk2/GST-cyclin D2+no substrate; lane 2, Cdk2/GST-cyclin D2+substrate; lane 3, Cdk4/GST-cyclin D2+no substrate; lane 4,
Cdk4/GST-cyclin D2+substrate; lane 5, Cdk5/GST-cyclin D2+no substrate; lane 6, Cdk5/GST-cyclin D2+substrate. Right panel, both Cdk5/
GST-p35 and Cdk5/GST-cyclin D2 were tested for their ability to phosphorylate histone H1, GST-Rb152 and His-dbpA(Cv). Lane 1, Cdk5/
GST-p35+no substrate; lane 2, Cdk5/GST-p35 incubated with 1 Wg histone H1; lane 3, Cdk5/GST-p35 kinase incubated with 0.25 Wg GST-
Rb152; lane 4, Cdk5/GST-p35 incubated with 5 Wg His-dbpA(Cv) ; lane 5, Cdk5/GST-cyclin D2+no substrate; lane 6, Cdk5/GST-cyclin D2 in-
cubated with 1 Wg histone H1; lane 7, Cdk5/GST-cyclin D2 incubated with 0.25 Wg GST-Rb152; lane 8, Cdk5/GST-cyclin D2 incubated with
5 Wg His-dbpA(Cv).
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ase assays. The insect cell expressed GST-dbpA(Cv) protein
gave the same results as the bacterially expressed GST-
dbpA(Cv) in its inhibition of the Cdk5/GST-p35 and the
Cdk4/GST-cyclin D1 kinase and not the Cdk2/cyclin A kin-
ase, whereas it was not a substrate for any of the kinases
tested (results not shown). Eukaryotic expression of GST-
dbpA(Cv) did therefore not give any drastic di¡erence in
the folding or post-translational modi¢cation of the polypep-
tide.
4. Discussion
DNA binding protein DbpA belongs to the Y-box protein
family. These proteins contain three domains: N-terminal do-
main, cold shock domain (CSD) and C-terminal domain. The
cold shock domain, comprising of 70 amino acids, is highly
conserved from prokaryotes to eukaryotes [23] and can bind
so called Y-boxes on DNA. The DNA binding depends on the
presence of inverted CCAAT motifs and £anking bases in
these Y-boxes. The N-terminal region of dbpA is rich in pro-
line and alanine residues which could potentially function as a
transcriptional regulation domain [24]. Several eukaryotic
genes contain a Y-box in their regulatory region. Ishii and
colleagues were the ¢rst to isolate dbpA via interaction with
the enhancer of the human epidermal growth factor receptor
gene and the promoter of the human c-erbB-2 gene [25]. The
dbpA protein has also been found to bind to the promoter
sequence of the leukosialin gene [21]. Furthermore, the dbpA
protein represses the expression of the I-AL gene of the major
histocompatibility complex [24] and the expression of the
stress-inducible gene grp78 [26]. The C-terminal domain of
dbpA is hydrophilic due to an alteration of groups of basic
and acidic amino acids, termed the charged zipper domain,
that presumably contributes to interactions with other pro-
teins [24]. This is the region we have isolated using the yeast
two-hybrid system (Fig. 2A). Surprisingly, it inhibits both
Cdk5 and Cdk4 activity. Further experiments should reveal
whether full length dbpA has the same e¡ect on Cdk5 and
Cdk4 as its C-terminal fragment.
We have not found the consensus sequence (X-S/T-P-X-K/
R-X-) [27], which is typical of a site phosphorylated by a Cdk,
in dbpA(Cv) (EMBL-PROSITE database). Our data con¢rm
that dbpA(Cv) is neither a substrate for Cdk5 nor for Cdk4
(Fig. 4D, right panel, lane 4 and Fig. 5A, lane 5 respectively).
However, it should be noted that the protein has three poten-
tial protein kinase C phosphorylation sites. We do not know if
these sites are utilized at all.
Although Cdk5 is expressed in both proliferative and di¡er-
entiated cells, its expression is relatively abundant in nerve
and muscle cells. Since dbpA mRNA is present in HeLa cells,
the dbpA protein must also be present in proliferating cells.
DbpA may therefore play a role in inhibiting Cdk5 during the
cell cycle.
The p35 protein, the only known activator of Cdk5, is
solely expressed in di¡erentiated nerve cells. Cdk5 kinase ac-
tivity (with p35 as its activator) could therefore be responsible
for the onset of di¡erentiation of nerve cells and possibly of
muscle cells [9^12]. However, Cdk5 kinase activity should be
blocked during terminal di¡erentiation. Since both Cdk5 and
p35 are present in terminally di¡erentiated cells, other pro-
teins should be involved in preventing this complex to be
active in these cells. We would like to propose that dbpA is
probably a speci¢c inhibitor of Cdk5. This assumption is
supported by results from Northern blot analyses which
show that dbpA is highly expressed in skeletal muscle and
heart as compared to other tissues ([21]; and our results,
Fig. 3). Cdk5 is reported to phosphorylate neuro¢lament pro-
teins and tau protein in vitro. Neuro¢lament proteins are also
hyperphosphorylated in patients su¡ering from Lewy body
pathologies, whereas the tau protein is hyperphosphorylated
in patients su¡ering from Alzheimer’s disease. Since the dbpA
transcript was not detected in the brain ([21]; and our results,
Fig. 3) other proteins may be responsible for inhibition of
Cdk5 in the brain. It is also possible that dbpA is expressed
in a particular section of the brain whose mRNA was not
present in the commercial blot used for Northern analysis.
It is known that the Cdk4 kinase is responsible for phos-
phorylation of pRb early in the G1 phase of the cell cycle and
has a very important function in cycling cells [28]. One can
speculate that binding of dbpA to the Cdk4 protein allows
inhibition of its kinase activity which thereby causes cell cycle
arrest. Probably, this is what occurs in di¡erentiated cells
where it is essential that Cdk4 activity is inhibited. In cycling
cells however, dbpA should be bound to Cdk5 to prevent the
premature onset of di¡erentiation. When Cdk5 is activated
during di¡erentiation, dbpA may switch its binding allegiance
to Cdk4, resulting in the latter’s inhibition and causing a cell
cycle block. Later, terminally di¡erentiated cells may again
have dbpA bound to Cdk5 to maintain the kinase in its in-
active form.
It has been reported that dbpA activates the transcription
of thymidine kinase [29]. This may also suggest that dbpA is
expressed at the beginning of S phase of the cell cycle and
FEBS 21716 15-3-99
Fig. 5. His-dbpA(Cv) is not a substrate for Cdk4/GST-cyclin D1
but instead inhibits the kinase. Comparison of the inhibition of
Cdk5/GST-p35 and Cdk2/GST-cyclin A kinases by His-dbpA(Cv).
A: His-dbpA(Cv) inhibits Cdk4/GST-cyclin D1-mediated phospho-
rylation of GST-Rb152 (0.5 Wg) and is not phosphorylated by the
kinase. Lane 1, Cdk4/GST-cyclin D1+no substrate; lane 2, Cdk4/
GST-cyclin D1+substrate (the lower band is a breakdown product
of GST-Rb152); lane 3, Cdk4/GST-cyclin D1+substrate+1 Wg His-
dbpA(Cv) ; lane 4, Cdk4/GST-cyclin D1+substrate+6 Wg His-
dbpA(Cv) ; lane 5, Cdk4/GST-cyclin D1+6 Wg His-dbpA(Cv). B:
Comparison of inhibition of the Cdk5/GST-p35 and Cdk2/GST-cy-
clin A-mediated phosphorylation of histone H1 (1 Wg) by His-
dbpA(Cv). Lane 1, Cdk2/GST-cyclin A+substrate; lane 2, Cdk2/
GST-cyclin A+substrate+0.5 Wg His-dbpA(Cv) ; lane 3, Cdk5/GST-
p35+substrate; lane 4, Cdk5/GST-p35+substrate+0.5 Wg His-
dbpA(Cv) ; lane 5, Cdk5/GST-p35+substrate+6 Wg His-FKBP12 (an
unspeci¢c protein). The results show that His-dbpA(Cv) inhibits
Cdk5/GST-p35 but not the Cdk2/GST-cyclin A kinase.
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may thus block Cdk4 activity at a point in the cell cycle where
Cdk4 activity is no longer needed. This assumption may be
equally valid if Cdk5 were to be responsible for the onset of
di¡erentiation. It is noteworthy that interactions between
dbpA and Cdk5 or Cdk4 provide a link between unique signal
transduction pathways and allow for alteration in gene ex-
pression. However, the true role of dbpA in cycling and
post-mitotic cells needs to be evaluated through further cellu-
lar analyses.
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